New York, March 2, 2026, 09:49 EST — Regular session.
- BillionToOne slipped roughly 2% early, trading at $74.83 after closing Friday at $76.33.
- The diagnostics firm will release fourth-quarter and full-year 2025 results after markets close on March 4.
- Investors want to hear the latest on prenatal and oncology testing growth, plus details on the company’s outlook for 2026.
BillionToOne opened Monday’s session on the back foot, dropping roughly 2% to $74.83. The stock has bounced between $73.09 and $74.83 so far, as broader U.S. indexes slid as well.
The announcement lands just before BillionToOne is set to deliver its Q4 and full-year 2025 results, which will hit after the bell on Wednesday, March 4. Executives are holding a conference call at 4:30 p.m. Eastern.
The timing is key here, with the stock still trying to gain traction just a few months out from its debut. This year, traders haven’t hesitated to sell into pops in newly listed healthcare names—especially those with shaky visibility on margins or payer coverage.
BillionToOne in January projected 2026 revenue between $415 million and $430 million, telling investors it’s aiming for positive GAAP operating income that year. CEO Dr. Oguzhan Atay described the plan as “a clear roadmap” and emphasized “disciplined execution.” Billiontoone
BillionToOne set its IPO price at $60 per share in November, offering up 4,551,100 shares and aiming to raise around $273.1 million before fees and expenses, according to the company.
Based in Menlo Park, California, the company’s focus is molecular diagnostics—think prenatal tests and cancer screening. Offerings include non-invasive prenatal screening (NIPT) and “liquid biopsy,” a blood-based test that can detect tumor DNA. Reuters
Investors are zeroed in on test volumes, reimbursement dynamics, and whether the company shifts spending as it ramps up its prenatal lineup and Northstar oncology platform in Wednesday’s report. A tweak to the 2026 forecast might drive sentiment through the week.
Wall Street analysts, according to MarketBeat, are split, pegging an average price target for the stock in the mid-$130s. The range is broad—anywhere from roughly $110 to $160—which highlights the ongoing debate over its growth prospects and valuation.
But there’s not much margin for error here. Should the company’s update signal weaker adoption, tighter pricing, or rising lab and commercial costs, the shares might remain weighed down.
